Regeneron, Sanofi Expand Alliance With $1B Upfront, $7B Milestones
Regeneron and Sanofi have expanded their antibody alliance to co-develop four long-acting immunology antibodies. Regeneron will receive a $1 billion upfront payment and up to $7 billion in potential milestones, with costs and profits to be shared 50:50 globally.
Regeneron and Sanofi have expanded their antibody alliance to co-develop four long-acting immunology antibodies. Regeneron will receive a $1B upfront payment and up to $7B in potential milestones, with costs and profits shared 50:50 globally.